Funding
Total funding raised: €6.73M across grants, equity, and loans. 64% non-dilutive.
Funding mix
| Source | Amount | % |
|---|---|---|
| Grants (non-dilutive) | €3,562,253 | 52.9% |
| Equity investment | €2,375,382 | 35.3% |
| Loans (non-dilutive) | €795,000 | 11.8% |
| Total | €6,732,635 | 100.0% |
Equity rounds
Pre-seed (2020-2022)
Raised €342,000 from business angels (cash and convertible loans).
Seed Round (September 2024)
Closed on 24 September 2024: €2,033,382 raised, led by Mutua Ventures, with strategic investors from the healthcare and telecom sectors: Angels Capital, Ribera Salud, Biozell Ventures, and Telefónica Open Innovation. Full per-investor detail is available in due diligence.
Grants
Non-dilutive funding represents over half of total capital raised. The largest grant, the CDTI Seal of Excellence (€2.49M), is a non-repayable CDTI grant (Next Generation EU) awarded on the basis of the EU's Horizon Europe Seal of Excellence.
R+D grants (€2.78M, including the €2.49M CDTI flagship), internationalisation (€295K) and other regional programmes (~€485K) make up the €3.56M grants total. The full grant-by-grant list, with amounts, is available in due diligence.
Three applications are in evaluation, with ~€1.5M of non-dilutive capital requested (final awards may be lower): Red.es RedIA Salud (VALIDERMIA), CDTI Misiones 2026 (dIAna, Almirall consortium), and Plan 2i 2026 (VALIDERMIA). Resolutions expected between September and Q4 2026. Amount-by-programme detail is available in due diligence.
Loans
Soft loans with low average interest from public and regional lenders (ENISA, Aquisgrán, Solventis, Santander), €795,000 in total. Lender-by-lender detail is available in due diligence.
Full detail
Full per-investor, grant and loan detail is available in due diligence.